Another Covid-19 breakthrough as researchers find inhaled multiple sclerosis drug proven to work

Just 13 per cent of patients given SNG001 fell ill enough to need intensive care. That was compared to 22 per cent of Covid patients who received a placebo. SNG001 uses naturally-occurring protein interferon beta which fights viruses